Immunocore Ltd.. (10/4/17). "Press Release: Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer". Oxford & Conshohocken, PA.

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Organisation	Immunocore Ltd.
	Group	Immunocore (Group)
	Organisation 2	Eli Lilly & Co. Inc. (NYSE: LLY)
	Group	Eli Lilly (Group)
	Product	tebentafusp-tebn (IMCgp100)
	Product 2	TCR engineering technology (T-cell receptor engineering technology)
	Person	Hotchkiss, Andrew (Draupnir Bio 202106– CEO before Dermira + Immunocore + Lilly)
	Person 2	Forster, Eliot (F-Star 201810– CEO before Immunocore + Creabilis + Solace Pharmaceuticals + Pfizer + GSK)

Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Andrew Hotchkiss as Chief Commercial Officer (CCO).

Andrew joins Immunocore from Eli Lilly & Co, where he held a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unity Leader Oncology and President Biomedicines Business Units, Australia, Canada and Europe.

Andrew will be based at Immunocore’s headquarters in Oxford, UK and, as CCO, will oversee Immunocore’s global commercial operations and the preparation of the implementation of the Company’s future commercial strategy.

Eliot Forster, Chief Executive Officer at Immunocore, said: “We are delighted to welcome Andrew to Immunocore where he will be instrumental in preparing the Company for its first potential product launch with IMCgp100, and ultimately the commercialisation of other assets as they move through clinical development. The combination of Andrew’s vast international commercial knowledge and extensive global leadership experience at Lilly is invaluable and will complement our outstanding leadership team.”

Andrew Hotchkiss commented: “Immunocore is a truly unique company, whose TCR technology sets it apart from the crowd and underpins its aspiration to change medical practice in the most challenging disease areas. The opportunity to work closely with such a dynamic and passionate team in a company with the potential to have such a radical impact on medical practice in areas from cancer to infectious disease was too good to turn down. I look forward to playing a part in the Immunocore story.”

- Ends -

For more information, please contact:

Immunocore
Eva-Lotta Allan, Chief Business Officer T: +44 (0)1235 438600 E: info@immunocore.com Follow on Twitter: @Immunocore

Consilium Strategic Communications
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton T: +44 (0)203 709 5700 E: Immunocore@consilium-comms.com

Follow on Twitter: @ConsiliumHC

Notes for editors

About Immunocore

Immunocore is the world’s leading T cell receptor (TCR) company, a global biotech striving to change medical practice in the most challenging disease areas. Immunocore is focused on delivering first-in-class biological therapies for patients, deploying its pioneering soluble TCR technology. This new class of TCRbased bi-functional drug with ultra-high affinity for intracellular cancer targets is based on synthetic, soluble TCRs that naturally recognize cells containing disease specific targets and selectively kill them. Unlike most biological treatment modalities, this technology can address both extra and intracellular disease targets. These TCR-based therapeutics can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies. Immunocore’s TCR technology has a broad applicability to a wide range of intracellular targets and disease indications including solid tumours, infectious diseases and autoimmune diseases.

Across the oncology pipeline, Immunocore has collaborations with Genentech, GlaxoSmithKline, MedImmune (the biologics division of AstraZeneca) and a co-discovery and co-development partnership with Lilly across a range of solid tumours. Immunocore’s wholly-owned lead programme, IMCgp100, is in a pivotal monotherapy trial in patients with metastatic uveal melanoma. This study trial on the first ever demonstration of compelling single agent efficacy in a solid, ‘cold’, low mutation tumour, which is challenging for most currently available immuno-oncology agents to address. The Company has also entered into combination trials with IMCgp100 in metastatic cutaneous melanoma with MedImmune and in metastatic uveal melanoma with Lilly.

Immunocore is headquartered near Oxford, UK, with offices near Philadelphia, US. The Company is privately held by a broad international and private investor base. For more information, please visit www.immunocore.com.

Record changed: 2023-06-05